Ask AI
H.R. 1730

Cancer Drug Parity Act of 2019

Cancer Drug Parity Act of 2019

This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Referred to the Subcommittee on Health.

Rep. Higgins, Brian [D-NY-26](D-NY)Sponsor
170 cosponsors105 D65 R
170cosponsors1committees4actions1related bills5subjects
  1. Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  2. IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  3. IntroReferralIntro-H

    Introduced in House

  4. IntroReferral1000

    Introduced in House

Cancer Drug Parity Act of 2019 — Informed